Whitepapers
Patient Journey Empowerment: Realizing the potential for patients and your brand
Whitepaper
Dec 11, 2023
Competitive Planning and Response: Where to focus for sustained success
Whitepaper
Nov 22, 2023
Penetrating the CNS – Strategic Implications of an Increasingly Flexible FDA
Whitepaper
Nov 21, 2023
Half-time in the EU HTA Regulation Roll Out
Whitepaper
Sep 22, 2023
Before You Start the Strategic Planning Cycle: 5 essential things to streamline your approach
Whitepaper
Sep 11, 2023
ICER Value Assessment Framework Update 2023
Whitepaper
Aug 31, 2023
Advancing Clinical Development by Strategically Leveraging Advisory Boards
Whitepaper
Aug 11, 2023
CAR T-Cell Therapies in the US, UK and EU4
The Lumanity team (then “BresMed”) supported the first successful HTA submissions to NICE in CAR T-cell therapy, and years on from the first approval, access to these innovative new therapies has expanded markedly. To help understand how countries currently evaluate established novel therapies, we have produced a whitepaper examining the primary factors that drive reimbursement decisions for CAR T-cell therapy across the US, UK and EU4 (France, Germany, Italy and Spain).
Whitepaper
Aug 8, 2023
Making a Case for Using Real World Data to Model Patient Entry in Budget Impact Analyses
Whitepaper
Jul 13, 2023
The Strategic Narrative Thread: Connecting brand messaging and execution
Whitepaper
Jul 12, 2023
A Practical Guide to Segmentation: What, who, why, and how?
Whitepaper
Jul 5, 2023
Scenario-based Strategy in Tumultuous Times: How pharma executives can conquer uncertainty
Learn more about the key trends driving industry uncertainty and how pharma companies can best adapt their strategies to outcompete and thrive.
Whitepaper
Jun 28, 2023